Cause analysis of conversion to biologics in spondyloarthritis patients with poor response to conventional treatment

ConclusionAge and uveitis are related to conversion to biologics therapy. The early combination of sulfasalazine and thalidomide with NSAIDs may lower the probability of conversion to biologics therapy in the later stage and offer a new option for patients with limited use of biologics in SpA patients.Key Points• Patients’ move to biologics may be caused mostly by inadequate disease control by conventional oral medications.• Regardless of axial vs. peripheral joint involvement, combination drug therapy was superior to single drug therapy in controlling SpA and decreasing the probability of conversion to a biological agent.• For SpA patients who are not candidates for biologics due to contraindications or other reasons, early combination application of NSAIDs, sulfasalazine, and thalidomide may be a new choice.

Source: Clinical Rheumatology - November 11, 2023 Category: Rheumatology Source Type: research